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1. Introduction
1.1. The need for engineered bone
While bone is inherently capable of regeneration, complications such as excessive bone loss
impede healing, necessitating the use of bone grafts. In the United States alone, an estimated
15 million fractures occurs annually, including 1.6 million hospital admissions for traumatic
fractures and 2 million osteoporotic fractures, costing over 60 billion dollars and calling for 1.6
million bone grafts each year [1]; a growing demand for bone grafts is similarly observed
worldwide. In such applications, autologous bone grafts continue to be regarded as the “gold
standard” for bone repair. However, this may not be practicable in cases involving large bone
loss. Additionally, patients suffer from significant donor site morbidity, as well as poor
outcomes in older patients [2, 3]. Allogeneic bone grafts may alternatively be used, but pose
potential risks of immune rejection and pathogen transmission [4]. Additionally, the limited
number of donors is unable to cope with the clinical demand. Consequently, alternative
approaches to provide efficacious and reliable bone grafts are being actively pursued.
The advent of tissue engineering, where the aim is to generate functional tissue, has raised the
possibility of engineering bone in vitro [5]. Over the past few decades, a wealth of progress in
bone tissue engineering has been achieved, particularly in cell sources, developing biocom‐
patible and biodegradable scaffolds, designing bioreactors to enhance in vitro osteogenic
priming, and identifying growth factors that can induce or promote endogenous bone and
vascular formation [6]. Numerous pre-clinical trials with various animal models have pro‐
duced optimistic results [7].Despite the initial optimism, the lack of translation into a clinical
setting suggests significant issues remain, including optimisation of cell sources, choice of
biomaterial, in vitro preparation and the mode of delivery.
© 2013 Bao et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.2. Normal bone anatomy
As seen in figure 1, bone tissue is organised into cancellous or cortical bone. Cancellous bone
(also referred to as trabecular bone or spongy bone), is porous, providing structural support
and organisation for bone marrow interspersed inside. In contrast, cortical bone is the compact
bone surrounding the marrow space, and confers mechanical strength to bone. The outer layer
that covers the surface of cortical bones is the periosteum, containing mainly blood vessels and
osteoblasts, which are activated during appositional growth and bone repair [8].
Figure 1. Schematic overview of bone, depicting gross overview, and cellular distribution. (Figures were produced us‐
ing Servier Medical Art) In particular, osteoprogenitors may be found abundantly in the periosteum and bone marrow,
where they perform critical roles in bone repair. Additionally, bone is observed to be highly vascularized, in both the
intramedullary canal and periosteal region.
The basic functional unit of the cortical bone is the osteon (or haversian system) which contains
cells and extracellular matrix organised in a lamellar pattern, surrounding the haversian canal,
in which nerves and blood vessels reside [9]. Within the osteon, osteoblasts and the mature
osteocytes exist, contributing to the generation and maintenance of ECM that gives bone it's
structural strength [10]. These are derived from osteoprogenitors that reside in the bone
marrow and periosteum. Also present are the myeloid-derived osteoclasts that mediate bone
resorption; further elaboration on the roles and functions of these cells is provided below.
Compared to other tissue, the ECM found in bone is highly mineralized to confer mechanical
strength. Calcium and phosphate are found in bone ECM in the form of hydroxyapatite crystal
(Ca10(PO4)6(OH)2), interspersed with Type I collagen [11], while the exact composition remains
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to be elucidated [12]. This unique composite of biological molecules (collagen) and inorganic
minerals (calcium phosphate) provides bone with high mechanical strength, as well as
toughness to resist impact.
1.3. Bone physiology
Bone is a highly dynamic tissue, which undergoes constant remodelling through one's lifetime.
Homeostasis is achieved through the combined actions of osteoprogenitors, osteoblasts,
osteocytes, as well as osteoclasts. In general, bone formation is effected through the prolifer‐
ation of osteoprogenitor cells and differentiation into osteoblasts, which are responsible for
the regulation of mineralization and collagen production through expression of functional
proteins such as osteocalcin and alkaline phosphatase [13, 14]. Osteoblasts which get trapped
in the ECM eventually differentiate to mature osteocytes forming syncytial networks that
function to support bone structure and metabolism. Bone actively undergoes remodelling in
response to environmental stimuli, such as physiologic influences or mechanical forces, in
accordance with Wolff’s law. This process involves a balance between bone formation as
described above, as well as bone resorption by osteoclasts [15], and it is crucial for renewing
bone, to maintain bone strength and mineral homeostasis [16].
The bone is able to undergo significant regeneration in response to trauma and fractures.
Regeneration progresses through the three phases of inflammation, repair and remodelling
[17]. The immune system can be seen to be intricately involved in the process of healing and
inflammation is required for effective healing [18]. Subsequently, the repair and remodelling
processes are initiated in the periosteum, which contain a rich population of osteoprogenitors
and osteocytes that proliferate and migrate to the defect site, forming a bony bridge to effect
fracture healing. When this bridging does not happen, hypertrophic non-union occurs,
necessitating the use of bone grafts.
2. Stem cell sources
Over the last few decades, stem cells have emerged as a key player in tissue engineering, both
for in vitro generation of bones, and in vivo bone regeneration. Two hypotheses have been
proposed to describe the mechanism of healing affected by stem cells. In the conventional
approach, osteogenic stem/progenitor cells are proposed to participate in new bone through
direct differentiation into functional tissue. More recently, it has emerged that trophic factors
secreted by administered stem/progenitor cells can promote functional tissue regeneration
[19]. Much research is currently focused on understanding the influence of stem cell origin and
culture conditions on clinical outcome.
2.1. Adult stem cell sources
The human body retains a small amount of osteoprogenitor cell population with differentiation
potential even in adulthood. The main osteogenic progenitor cells – mesenchymal stem cells
(MSCs) are considered to consist of a variety of cell populations, with no unique marker to
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delineate a MSC to-date [20]. Therefore, in some studies, the term “mesenchymal stem cells”
is used to represent osteoprogenitor cells [21]. The current consensus on the characteristics of
a bona-fide MSC should include: 1) expression of cell-surface markers which are non-haemo‐
poietic, non-endothelial and incorporates a number of other cell-surface markers, including
CD73, CD105 and CD90, and 2) the capacity for tri-lineage differentiation into osteocytes,
chondrocytes and adipocytes [22].Common sources of MSCs include bone marrow, fat tissue
and the periosteum [23].
MSCs are most abundantly found in the bone marrow (BM), and BM-MSCs are widely utilised
for both autologous or allogeneic transplantations [20]. BM-MSCs can be easily expanded in
culture, and induced to differentiate into osteoblasts through culture in a high phosphate
environment [24]. In tissue engineering applications, BMMSCs have been used to generate
bone graft by loading into appropriate scaffolds, followed by osteogenic culture [25],. BM-
MSCs may offer favourable characteristics, including availability as an autologous cell source,
and thus, non-immunogenic cell source [26]. In contrast to suggestions that BM-MSC are
immunoprivilleged and thus suitable for allogeneic – unmatched transplantation [27], a few
studies have emerged that reported rejection of murine BM-MSCs following infusion into
immune competent recipients [28]. Besides, adult BM-MSCs though advantageous in autolo‐
gous source availability, have shown relatively low efficiency in osteogenic differentiation in
vivo in several comparative studies [29, 30].
The periosteum is involved in extraosseous fracture repair, and is thus also thought to contain
osteoprogenitors. Indeed, stem cells derived from periosteal tissue showed better mineraliza‐
tion and neovascularization ability than adult bone marrow derived cells and demonstrating
good efficacy in healing a calvarial defect model [31]. However, its potential as a cell source is
limited by the low volume of periosteum which can be harvested, as well as the complexity of
the harvesting process [32]. Further optimization in terms of isolation and culture conditions
will be required before it can be a practical source.
Adipose tissue represents another potential source of osteogenic stem cells [33]. Adipose
derived stem cells (ADSCs) can be isolated from fat tissues harvested by liposuction or surgical
fat section, which are typically considered medical waste [34]. Similar to BM-MSCs, ADSCs
respond to osteogenic induction through upregulation of alkaline phosphatase and other key
osteogenic proteins, and differentiate into osteoblasts capable of depositing minerals [35].
Additionally, ADSCs have been shown to ne efficacious in bone repair, facilitating the repair
of critical size defects in both calvarial and femoral segmental defects [36, 37]. However, the
efficacy of bone repair by using ADSCs alone is relatively low compared with marrow-origin
MSCs and more primitive MSCs [38, 39].
The adult stem cells represent a rich autologous source for bone tissue engineering, and the long-
history study accumulate mature methodology to facilitate their application in pre-clinical trials
or even clinical trial [40, 41]. Yet the low efficiency of in vitro bone generation and in vivo bone
regenerative capacity may call for optimized induction strategy or alternative sources.
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2.2. Embryonic Stem Cell (ESC) and induced Pluripotent Stem Cell (iPSC)
In the last decade, the osteogenic induction of embryonic stem cells (ESCs) and the creation of
induced pluripotent stem cells (iPSCs) presented new cell sources for bone tissue engineering
[42, 43]. However, expansion of ESCs and iPSCs to clinically useful numbers is logistically
challenging, and autologous use is not possible in the case of embryonic stem cells. Moreover,
precise control of differentiation is necessary before applying to clinical use. This is especially
so since the presence of undifferentiated "rogue cells" may result in tumour formation after
transplantation [23].
ESCs are defined by their pluripotency, and can be induced into osteogenic cells through
different  methods  in  vitro  [44,  45].  It  is  showed that  human ESCs can be  induced into
osteogenic  cells  and  form  mineralized  bone  in  vivo  without  presence  of  teratoma  [46].
However,  more  investigations  will  be  required  to  address  the  potential  of  teratoma  in
embryonic stem cells transplantation. Mature methods for specific osteogenic differentia‐
tion are also needed to overcome non-specific differentiation before clinical implementa‐
tion can be contemplated.
As an alternative, iPSCs have recently emerged as a potential cell source for regenerative
medicine [43]. Compared to ESCs, iPSCs face fewer ethical challenges, and are able to serve
as an autologous cell source. iPSCs have been successfully differentiated into osteoblasts
like  cells  [47],  or  through  induction  into  a  MSC  phenotype  [48,  49],  allowing  ready
expansion  of  the  iPSC-derived  MSC  before  their  direct  differentiation  into  osteoblasts.
However, similar issues to that of ESC remain, and concerns remain over the potency of
the  cells.  Additionally,  the  concept  of  reprogramming  remains  poorly  understood,  and
leaving questions on the fate of cells in vivo [49]. Therefore, although the differentiation
capacity qualifies the iPSC as a potential source for bone engineering, yet a lot more efforts
have to be done before it can be competent.
2.3. Fetal stem cell sources
Compared with adult stem cells, fetal stem cells are relatively more primitive, and have higher
proliferative and differentiation capacity. MSCs have been derived from various fetal tissues
in early to mid-gestation, including the blood, bone marrow, liver, pancreas, kidney thymus
and bone [50]. Of these, fetal BM-MSC has shown particular utility for bone tissue engineering
as reviewed extensively by Zhang et al [19]. However, its availability may be limited by ethical
issues especially where fetal tissues are used to derive MSC [51].
As an alternative source, MSC has also been derived from umbilical cord blood at term
gestation, albeit at very low frequencies [51], with optimised protocols achieving up to 60%
success in its derivation [52]. Aside from the cord blood, MSC has also been derived from the
umbilical cord vessels and matrix, the placenta and fetal membranes [53]. Although these
sources of MSC are plentiful and readily harvested, their utility for bone tissue engineering is
somewhat limited compared to fetal bone marrow derived MSC [19, 29].
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2.4. Conclusion
Stem cell sources for bone tissue engineering have been widely explored recently, and several
studies have been conducted to compare the different cell sources [21, 29, 30, 44, 54]. Table 1
below summarizes some of these studies and compares the main properties of different stem
cell sources.
Cell origin Proliferationrate
Osteogenic
capacity
Mineral
deposition Main Limitations Key Advantages
Adult bone
marrow Low Medium Medium Limited efficiency
Autograft
accessibility
Adipose Low Low Low Low efficiency Autograftaccessibility
Periosteum High High High Less resource Autograftaccessibility
Embryonic
stem cell High Medium High
Non-specific
differentiation
Least mature,
highest potential
Cord blood Medium High Low Autograftnon-accessibility
High potential,
good efficiency
Fetal bone
marrow High Very high Very high
Autograft
non-accessibility Highest efficiency
Table 1. A comparison of stem cell sources based on comparative studies
3. Biomaterials
The development of scaffolds is a major aspect in bone tissue engineering research. On one
hand, these scaffolds should be rigid and resilient since they function as the main supporting
frame work of bone graft. On the other hand, they should also be porous, biocompatible,
osteoinductive and osteoconductive so that bone tissue can regenerate within the scaffolds
[55]. In addition, a relatively slow degradation rate is crucial to provide mechanical support
prior to complete native bone regeneration. The scaffolds can be made of natural, synthetic
materials or suitable composites.
3.1. Natural materials
Natural materials applied to bone tissue engineering include biological polymers (such as
collagen and hyaluronic acid), as well as inorganic materials (such as hydroxyapatite and tri-
calcium phosphate). Intuitively, naturally occurring materials in native bone, such as collagen,
are favoured as the possess the innate biological cues that favour cell attachment and promote
chemotactic response when being implanted in vivo [56]. When used as grafts implanted in
vivo, those polymers are readily remodelled by the resident cells to the internal environment.
Besides, the fibrous property of polymers allows manipulation during scaffold fabrication, so
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that the scaffold’s structure and porosity can be easily controlled [57, 58]. However, the
telopeptide within these polymers may be immunogenic, and some of the polymer’s nature
(poor inherent rigidity and high degradation rate) limit their application in bone repair.
The main minerals in bone matrix, hydroxyapatite (HA) and tri-calcium phosphate (TCP), are
other candidates for bone scaffolds. Their mechanical properties are able to provide the
mechanical support at the defect area after transplantation. However, these minerals are
inherently brittle, and may perform poorly in response to impact. Currently, they are usually
combined with polymer materials with higher fracture toughness to achieve optimized
performance in bone tissue engineering application [59].
3.2. Synthetic materials
As compared to natural materials, synthetic materials may be designed and customised for
highly specified chemical and physical properties. These properties contribute to controllable
mechanical properties of the scaffolds, including tensile strength, resiliency and degradation
rate and to tailor desirable biological outcomes, such as reducing risks of toxicity, immuno‐
genicity and infectionscan [60].Synthetic materials, however, lack bioactive properties such as
biocompatibility, osteoinductivity and osteoconductivity, necessitating further modification
prior to use.
The most often used synthetic materials for three dimensional scaffolds are saturated poly-α-
hydroxy esters, including poly lactic acid (PLA), poly glycolic acid (PGA), poly lactic-co-
glycolic acid (PLGA), and poly caprolactone (PCL) [60]. They can be processed by techniques
such as gas forming, phase separation, fused deposition, and 3D printing [61-64]. The choice
of polymers and fabrication techniques for three dimensional scaffolds used in tissue engi‐
neering are a major aspect in material science, and much progress in this field has been made
in the last few decades [65].
As most materials alone showed some form of limitations, now researchers mostly design and
fabricate composite materials that combine polymers and inorganic minerals, to let the
different nature of materials complement each other, and attain optimal and controllable
degradation rate and mechanical properties. The combination can be varies and the fabrication
methods are diverse [66].
4. Emerging research theme: Addressing the need for vascularisation
4.1. Vascularisation as limiting bottleneck
Much effort has been focused on generating tissue engineered bone grafts in vitro, and several
attempts have been made to heal bone defects with engineered grafts in vivo. The achievements
in bone tissue engineering led considerable progress in finding potent osteogenic cell sources
and suitable biomaterials, as well as the development of scaffolds and the use of bioactive
factors. Currently, the attention has gradually shifted to strategies to improve vascular
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formation in tissue engineered bones as it emerges as the most crucial factor in ensuring graft
survival and hence bone repair.
Having a network of blood vessels within a tissue-engineered graft is important for maintain‐
ing cellular survival particularly within the core of large bone grafts [67]. It has been shown
that after implantation, neo-bone tissues were found only at where a vascular network was
present [68]. Poor angiogenesis has been identified as the main reason for implant failure and
is currently acknowledged as a major challenge in tissue engineering [69-71].
Currently, there are various strategies that are under investigation for improving vasculari‐
zation in tissue engineered grafts. These include the induction of vascularization in vivo, the
design of scaffolds specific to improving vascularization, and prevascularization techniques
using coculture systems [72]. The prospect of functional vascularized bone graft for defect
healing brings a bright future for clinical application.
4.2. Induction of angiogenesis and vasculogenesis
Angiogenesis and vasculogenesis are natural vascularization process that occurs in tissue
development and wound healing. The endothelial cells function as the main mediator of neo-
vascularization through forming new blood vessels by angiogenesis and they can be expanded
by vasculogenesis. In some studies, endothelial cells were used to generate capillary-like
structure and connect vessels in vitro [73]. However, it is unclear as to whether these vascular
generation approaches are effective in inducing vascularization in engineered bone graft in
vivo.
In addition to directly using endothelial cells to form vessel network, some growth factors
related to angiogenesis are used as another method to improve vascularization in engineered
tissue. These factors include vascular endothelium growth factor (VEGF), platelet-derived
growth factor (PDGF) and fibroblast growth factor (FGF) [74]. A major advantage of utilizing
growth factors instead of living cells is that the risk of host rejection can be excluded. However,
it seems inefficient using growth factors alone, because of the random formation of new vessels
within implanted bone [68]. More importantly, the inappropriate delivery of growth factors
may induce excessive angiogenesis which could cause severe pathogenic process such as
tumour development, atheroscleosis, and proliferative retinopathies [68, 71].
4.3. Scaffold design to promote vascular formation
Aside from the selection of molecular and cellular mediator for effective vascularization, the
choice of material used is also closely related to the vascular formation ability of the engineered
bone graft. The scaffolds have been designed to allow vascular in-growth through a macro‐
porous structure and incorporating vascular cues such as with the use of growth factors and/
or cells, rather than just serving as osteoconductive surfaces [75].
Over the past years, the selection of material candidates for bone tissue engineering scaffolds
has been focused on the compatibility of bone cell attachment and growth. But now, much
attention has also been switched to homing vascular formation [76]. The materials can impact
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the vascularization outcome of the bone graft from two aspects: 1) supporting the endothelial
cells growth and forming vessels; 2) incorporating active molecules that help to introduce
vascular formation. For example, the usage of silk fibroin and polycaprolactone (PCL) as
components for 3D porous scaffolds exhibited a good support to endothelial cell growth and
consequent vascularization [69, 77]; while poly lactic-co-glycolic acid (PLGA) and poly lactide-
co-glycolide (PLG) scaffolds showed the ability to incorporate VEGFs and release them locally
so that angiogenesis was improved [78, 79].
Additionally, the structural properties, such as geometry and porosity can also affect the
angiogenic ability of the scaffolds. Narayan and Venkatraman reported that the pore size of
scaffolds have a profound influence on the growth of endothelial cells, with enhanced cell
growth with smaller pore sizes and lower interpose distances [80]. Currently, the influence of
scaffold design on its osteoconductivity and vascular conductivity is still unclear and deserves
more investigations [81].
4.4. The use of stem cells for neo-vascularisation
Compared to mature endothelial cells, stem/progenitor cell candidates has been shown to
exhibit higher proliferative capacity and differentiation potential [82]. Endothelial progenitor
cells undergo vasculogenesis and have been shown to improve vascularization through the
release of a milieu of angiogenic factors [83, 84].
In addition to using endothelial progenitor cells to induce vascularization, stem cell candidates
are also needed for bone formation. Therefore, a co-culture system of the cells from different
lineages has been proposed by various groups which reviewed comprehensively by Liu et all
[72]. Several attempts have been made in generating vascularized bone graft for defect healing
through co-culture systems, combine endothelial lineages with osteogenic cell types on
different types of scaffolds [85-89].We have recently shown that co-cultured human fetal
mesenchymal stem cells (hfMSC) and umbilical cord blood derived endothelial progenitor
cells (UCB-EPC) seeded on PCL-TCP macroporous scaffolds induced more neo-vasculariza‐
tion and better bone formation, compared with the use of hfMSC alone [88].
5. Summary
A large number of bone grafts are required annually for clinical treatment of severe bone
fracture. The limitations in autograft and allograft restricted their clinical application. Alter‐
natively, tissue engineering approach may offer a new solution to produce bone grafts for
clinical use. Over the last twenty years, tissue engineering of the bone has made remarkable
progress, although the problems of translating into clinical application still remain.
Various types of stem cells have been used to form mineralized bone in vitro. In contrast, there
were much fewer studies focused on the healing efficacy and its potential side effects. One
main barrier is the complicated in vivo environment, which has profound interactions with
the implanted cell types. This is especially so for allogeneic cells, where the host immune
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reaction is likely to play a very important role, with the macrophage system currently being
under intense investigations [90, 91].
The use of biomaterials and development of scaffolds are especially important for engineering
bone grafts, because they need to provide mechanical support during bone repair and bioactive
aspect for bone formation. In order to obtain optimal mechanical properties, and high
biocompatibility, numerous composite materials were designed to acquire integrated proper‐
ties from the individual components. Recently, more stringent requirements brought forth in
the scaffold design for complete bone healing efficacy, such as inducing neo-vascularization
during the formation of bone.
The achievements in engineering bone tissue so far are encouraging, while new challenges and
opportunities are bringing the perspective of bone tissue engineering to a new height in clinical
application. In the near future, tissue engineering approaches will achieve full tissue trans‐
plantation and engineered bone graft will be mature enough for bone fracture repair treatment.
Acknowledgements
JC received salary support from the National Medical Research Council, Singapore
(NMRC/CSA/012/2009).
Author details
Chao Le Meng Bao1, Erin Y. Teo1,2, Mark S.K. Chong1,3, Yuchun Liu1,3, Mahesh Choolani1 and
Jerry K.Y. Chan1,2,4
1 Experimental Fetal Medicine Group, Department of Obstetrics and Gynaecology, Yong
Loo Lin School of Medicine. National University of Singapore, Singapore
2 Department of Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore
3 Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang
Technological University, Singapore
4 Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore
References
[1] Keefe, O, & Mao, R. J. a. n. d J. Bone tissue engineering and regeneration: from discovery to
the clinic-an overview. Tissue engineering. Part B, Reviews, (2011). , 389-392.
Regenerative Medicine and Tissue Engineering608
[2] Banwart, J. C, Asher, M. A, & Hassanein, R. S. Iliac crest bone graft harvest donor site
morbidity. A statistical evaluation. Spine, (1995). , 1055-1060.
[3] Goulet, J. A, et al. Autogenous iliac crest bone graft- Complications and functional assess‐
ment. Clinical Orthopaedics and Related Research, (1997). , 76-81.
[4] Betz, R. R. Limitations of autograft and allograft: New synthetic solutions. Orthopedics,
(2002). , S561-S570.
[5] Meinel, L, et al. Bone tissue engineering using human mesenchymal stem cells: effects of
scaffold material and medium flow. Annals of biomedical engineering, (2004). , 112-122.
[6] Salgado, A. J, Coutinho, O. P, & Reis, R. L. Bone Tissue Engineering: State of the Art and
Future Trends. Macromolecular bioscience, (2004). , 743-765.
[7] Cancedda, R, Giannoni, P, & Mastrogiacomo, M. A tissue engineering approach to bone
repair in large animal models and in clinical practice. Biomaterials, (2007). , 4240-4250.
[8] Buck, D. W, & Dumanian, G. A. Bone Biology and Physiology: Part I. The Fundamentals.
Plastic and Reconstructive Surgery, (2012). , 1314-1320.
[9] Ascenzi, M. G, & Roe, A. K. The osteon: the micromechanical unit of compact bone. Front
Biosci, (2012). , 1551-1581.
[10] Klein-nulend, J, Nijweide, P. J, & Burger, E. H. Osteocyte and bone structure. Curr Os‐
teoporos Rep, (2003). , 5-10.
[11] Aerssens, J, Dequeker, J, & Mbuyimuamba, J. M. BONE TISSUE COMPOSITION- BI‐
OCHEMICAL ANATOMY OF BONE. Clinical rheumatology, (1994). , 54-62.
[12] Rey, C, et al. Bone mineral: update on chemical composition and structure. Osteoporosis
International, (2009). , 1013-1021.
[13] Harada, S, & Rodan, i. a. n. d G. A. Control of osteoblast function and regulation of bone
mass. Nature, (2003). , 349-355.
[14] Szulc, P, et al. Biochemical markers of bone formation reflect endosteal bone loss in elderly
men- MINOS study. Bone, (2005). , 13-21.
[15] Clarke, B. Normal bone anatomy and physiology. Clinical journal of the American Soci‐
ety of Nephrology : CJASN, (2008). Suppl 3: , S131-S139.
[16] Cao, X. Targeting osteoclast-osteoblast communication. Nature medicine, (2011). ,
1344-1346.
[17] Claes, L, Recknagel, S, & Ignatius, A. Fracture healing under healthy and inflammatory
conditions. Nature reviews. Rheumatology, (2012). , 133-143.
[18] Cottrell, J, & Connor, J. P. O. Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone
Healing. Pharmaceuticals, (2010). , 1668-1693.
Bone Tissue Engineering
http://dx.doi.org/10.5772/55916
609
[19] Zhang, Z. Y, et al. The potential of human fetal mesenchymal stem cells for off-the-shelf bone
tissue engineering application. Biomaterials, (2012). , 2656-2672.
[20] Mauney, J. R, Volloch, V, & Kaplan, D. L. Role of adult mesenchymal stem cells in bone
tissue engineering applications: current status and future prospects. Tissue engineering,
(2005). , 787-802.
[21] Sakaguchi, Y, et al. Comparison of human stem cells derived from various mesenchymal tis‐
sues- Superiority of synovium as a cell source. Arthritis and rheumatism, (2005). ,
2521-2529.
[22] Dominici, M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells.
The International Society for Cellular Therapy position statement. Cytotherapy, (2006). ,
315-317.
[23] Robey, P. G. Cell sources for bone regeneration: the good, the bad, and the ugly (but promis‐
ing). Tissue engineering. Part B, Reviews, (2011). , 423-430.
[24] Prockop, D. J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science,
(1997). , 71-74.
[25] Bianco, P, & Robey, P. G. Stem cells in tissue engineering. Nature, (2001). , 118-121.
[26] Petite, H, et al. Tissue-engineered bone regeneration. Nature Biotechnology, (2000). ,
959-963.
[27] Krampera, M, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and
memory antigen-specific T cells to their cognate peptide. Blood, (2003). , 3722-3729.
[28] Eliopoulos, N, et al. Allogeneic marrow stromal cells are immune rejected by MHC class I-
and class II-mismatched recipient mice. Blood, (2005). , 4057-4065.
[29] Zhang, Z. Y, et al. Superior osteogenic capacity for bone tissue engineering of fetal compared
with perinatal and adult mesenchymal stem cells. Stem Cells, (2009). , 126-137.
[30] Kern, S, et al. Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Um‐
bilical Cord Blood, or Adipose Tissue. Stem Cells, (2006). , 1294-1301.
[31] Sakata, Y, et al. Osteogenic potential of cultured human periosteum-derived cells- A pilot
study of human cell transplantation into a rat calvarial defect model. Journal of Cranio-
Maxillofacial Surgery, (2006). , 461-465.
[32] Breitbart, A. S, et al. Tissue engineered bone repair of calvarial defects using-cultured peri‐
osteal cells. Plastic and Reconstructive Surgery, (1998). , 567-574.
[33] Zuk, P. A, et al. Multilineage cells from human adipose tissue: Implications for cell-based
therapies. Tissue engineering, (2001). , 211-228.
[34] Yoshimura, K, et al. Characterization of freshly isolated and cultured cells derived from the
fatty and fluid portions of liposuction aspirates. Journal of cellular physiology, (2006). ,
64-76.
Regenerative Medicine and Tissue Engineering610
[35] Kakudo, N, et al. Bone tissue engineering using human adipose-derived stem cells and hon‐
eycomb collagen scaffold. Journal of Biomedical Materials Research Part A, (2008).
A(1): , 191-197.
[36] Cowan, C. M, et al. Adipose-derived adult stromal cells heal critical-size mouse calvarial de‐
fects. Nat Biotech, (2004). , 560-567.
[37] Peterson, B, et al. Healing of critically sized femoral defects, using genetically modified mes‐
enchymal stem cells from human adipose tissue. Tissue engineering, (2005). , 120-129.
[38] Li, H. W, et al. Bone regeneration by implantation of adipose-derived stromal cells express‐
ing BMP-2. Biochemical and Biophysical Research Communications, (2007). , 836-842.
[39] Niemeyer, P, et al. Comparison of mesenchymal stem cells from bone marrow and adipose
tissue for bone regeneration in a critical size defect of the sheep tibia and the influence of pla‐
telet-rich plasma. Biomaterials, (2010). , 3572-3579.
[40] Giordano, A, Galderisi, U, & Marino, I. R. From the laboratory bench to the patients bed‐
side: An update on clinical trials with mesenchymal stem cells. Journal of cellular physiol‐
ogy, (2007). , 27-35.
[41] Henriksson, H. B, et al. Transplantation of human mesenchymal stems cells into interverte‐
bral discs in a xenogeneic porcine model. Spine (Phila Pa 1976), (2009). , 141-148.
[42] Gepstein, L. Derivation and potential applications of human embryonic stem cells. Circula‐
tion Research, (2002). , 866-876.
[43] Takahashi, K, et al. Induction of pluripotent stem cells from adult human fibroblasts by de‐
fined factors. Cell, (2007). , 861-872.
[44] Shimko, D. A, et al. Comparison of in vitro mineralization by murine embryonic and adult
stem cells cultured in an osteogenic medium. Tissue engineering, (2004). , 1386-1398.
[45] Bielby, R. C, et al. In vitro differentiation and in vivo mineralization of osteogenic cells de‐
rived from human embryonic stem cells. Tissue engineering, (2004). , 1518-1525.
[46] Kim, S, et al. In vivo bone formation from human embryonic stem cell-derived osteogenic
cells in poly(D,L-lactic-co-glycolic acid)/hydroxyapatite composite scaffolds. Biomaterials,
(2008). , 1043-1053.
[47] Tashiro, K, et al. Efficient Adipocyte and Osteoblast Differentiation from Mouse Induced
Pluripotent Stem Cells by Adenoviral Transduction. Stem Cells, (2009). , 1802-1811.
[48] Villa-diaz, L. G, et al. Derivation of Mesenchymal Stem Cells from Human Induced Pluri‐
potent Stem Cells Cultured on Synthetic Substrates. Stem Cells, (2012). p. N/A-N/A.
[49] Liu, Y, et al. One-Step Derivation of Mesenchymal Stem Cell (MSC)-Like Cells from Hu‐
man Pluripotent Stem Cells on a Fibrillar Collagen Coating. PLoS One, (2012). , e33225.
[50] Donoghue, O, & Chan, K. a. n. d J. Human fetal mesenchymal stem cells. Curr Stem Cell
Res Ther, (2006). , 371-386.
Bone Tissue Engineering
http://dx.doi.org/10.5772/55916
611
[51] Campagnoli, C, et al. Identification of mesenchymal stem/progenitor cells in human first-
trimester fetal blood, liver, and bone marrow. Blood, (2001). , 2396-2402.
[52] Bieback, K, et al. Critical Parameters for the Isolation of Mesenchymal Stem Cells from Um‐
bilical Cord Blood. Stem Cells, (2004). , 625-634.
[53] Shaw, S. W, David, A. L, & De Coppi, P. Clinical applications of prenatal and postnatal
therapy using stem cells retrieved from amniotic fluid. Curr Opin Obstet Gynecol, (2011). ,
109-116.
[54] Chen, D. Y, et al. Superior mineralization and neovascularization capacity of adult human
metaphyseal periosteum-derived cells for skeletal tissue engineering applications. Interna‐
tional Journal of Molecular Medicine, (2011). , 707-713.
[55] Burg, K. J. L, Porter, S, & Kellam, J. F. Biomaterial developments for bone tissue engineer‐
ing. Biomaterials, (2000). , 2347-2359.
[56] Stevens, M. M. Biomaterials for bone tissue engineering. Materials Today, (2008). , 18-25.
[57] Glowacki, J, & Mizuno, S. Collagen scaffolds for tissue engineering. Biopolymers,
(2008). , 338-344.
[58] Sundelacruz, S, & Kaplan, D. L. Stem cell- and scaffold-based tissue engineering ap‐
proaches to osteochondral regenerative medicine. Seminars in cell & developmental biolo‐
gy, (2009). , 646-655.
[59] Ramay, H. R. R, & Zhang, M. Biphasic calcium phosphate nanocomposite porous scaffolds
for load-bearing bone tissue engineering. Biomaterials, (2004). , 5171-5180.
[60] Rezwan, K, et al. Biodegradable and bioactive porous polymer/inorganic composite scaffolds
for bone tissue engineering. Biomaterials, (2006). , 3413-3431.
[61] Kim, S, et al. Poly(lactide-co-glycolide)/hydroxyapatite composite scaffolds for bone tissue
engineering. Biomaterials, (2006). , 1399-1409.
[62] Chen, V. J, & Ma, P. X. Nano-fibrous poly(l-lactic acid) scaffolds with interconnected spheri‐
cal macropores. Biomaterials, (2004). , 2065-2073.
[63] Hutmacher, D. W, et al. Mechanical properties and cell cultural response of polycaprolac‐
tone scaffolds designed and fabricated via fused deposition modeling. Journal of biomedical
materials research, (2001). , 203-216.
[64] Hutmacher, D. W. Scaffolds in tissue engineering bone and cartilage. Biomaterials,
(2000). , 2529-2543.
[65] Hutmacher, D. W, et al. State of the art and future directions of scaffold-based bone engi‐
neering from a biomaterials perspective. Journal of Tissue Engineering and Regenerative
Medicine, (2007). , 245-260.
Regenerative Medicine and Tissue Engineering612
[66] Hutmacher, D. W. Scaffold design and fabrication technologies for engineering tissues- state
of the art and future perspectives. Journal of Biomaterials Science-Polymer Edition,
(2001). , 107-124.
[67] Langer, R. Tissue engineering: perspectives, challenges, and future directions. Tissue engi‐
neering, (2007). , 1-2.
[68] Johnson, E. O, Troupis, T, & Soucacos, P. N. Tissue-engineered vascularized bone grafts:
basic science and clinical relevance to trauma and reconstructive microsurgery. Microsur‐
gery, (2011). , 176-182.
[69] Yu, H. Y, et al. Improved tissue-engineered bone regeneration by endothelial cell mediated
vascularization. Biomaterials, (2009). , 508-517.
[70] Koike, N, et al. Creation of long-lasting blood vessels. Nature, (2004). , 138-139.
[71] Santos, M. I, & Reis, R. L. Vascularization in Bone Tissue Engineering: Physiology, Cur‐
rent Strategies, Major Hurdles and Future Challenges. Macromolecular bioscience,
(2010). , 12-27.
[72] Liu, Y, Chan, J. K. Y, & Teoh, S. -H. Review on Vascularised Bone Tissue Engineering
Strategies: Focus on Coculture Systems. Journal of Tissue Engineering and Regenerative
Medicine, (2012). In Press.
[73] Niklason, L. E, et al. Functional arteries grown in vitro. Science, (1999). , 489-493.
[74] Ahrendt, G, Chickering, D. E, & Ranieri, J. P. Angiogenic growth factors: A review for
tissue engineering. Tissue engineering, (1998). , 117-130.
[75] Mastrogiacomo, M, et al. Role of scaffold internal structure on in vivo bone formation in
macroporous calcium phosphate bioceramics. Biomaterials, (2006). , 3230-3237.
[76] Cassell, O. C. S, et al. Vascularisation of tissue-engineered grafts: the regulation of angio‐
genesis in reconstructive surgery and in disease states. British Journal of Plastic Surgery,
(2002). , 603-610.
[77] Unger, R. E, et al. Growth of human cells on a non-woven silk fibroin net: a potential for use
in tissue engineering. Biomaterials, (2004). , 1069-1075.
[78] Kaigler, D, et al. VEGF Scaffolds Enhance Angiogenesis and Bone Regeneration in Irradiat‐
ed Osseous Defects. Journal of Bone and Mineral Research, (2006). , 735-744.
[79] Murphy, W. L, et al. Bone regeneration via a mineral substrate and induced angiogenesis.
Journal of Dental Research, (2004). , 204-210.
[80] Narayan, D, & Venkatraman, S. S. Effect of pore size and interpore distance on endothelial
cell growth on polymers. Journal of Biomedical Materials Research Part A, (2008).
A(3): , 710-718.
[81] Karageorgiou, V, & Kaplan, D. Porosity of 3D biornaterial scaffolds and osteogenesis. Bio‐
materials, (2005). , 5474-5491.
Bone Tissue Engineering
http://dx.doi.org/10.5772/55916
613
[82] Kim, S, & Von Recum, H. Endothelial stem cells and precursors for tissue engineering: cell
source, differentiation, selection, and application. Tissue engineering. Part B, Reviews,
(2008). , 133-147.
[83] Melero-martin, J. M, et al. Engineering robust and functional vascular networks in vivo
with human adult and cord blood-derived progenitor cells. Circulation Research, (2008). ,
194-202.
[84] Urbich, C, & Dimmeler, S. Endothelial progenitor cells- Characterization and role in vascu‐
lar biology. Circulation Research, (2004). , 343-353.
[85] Usami, K, et al. Composite implantation of mesenchymal stem cells with endothelial progen‐
itor cells enhances tissue-engineered bone formation. Journal of Biomedical Materials Re‐
search Part A, (2009). A(3): , 730-741.
[86] Seebach, C, et al. Endothelial Progenitor Cells and Mesenchymal Stem Cells Seeded onto be‐
ta-TCP Granules Enhance Early Vascularization and Bone Healing in a Critical-Sized Bone
Defect in Rats. Tissue Engineering Part A, (2010). , 1961-1970.
[87] Liu, Y, et al. Contrasting Effects of Vasculogenic Induction Upon Biaxial Bioreactor Stimu‐
lation of Mesenchymal Stem Cells and Endothelial Progenitor Cells Cocultures in 3D Scaf‐
folds Under In Vitro and In Vivo Paradigms for Vascularized Bone Tissue Engineering.
Tissue Eng Part A, (2012). In Press.
[88] Liu, Y, et al. Vasculogenic and Osteogenesis-Enhancing Potential of Human Umbilical Cord
Blood Endothelial Colony-Forming Cells. Stem Cells, (2012). , 1911-1924.
[89] Fuchs, S, et al. Contribution of outgrowth endothelial cells from human peripheral blood on
in vivo vascularization of bone tissue engineered constructs based on starch polycaprolactone
scaffolds. Biomaterials, (2009). , 526-534.
[90] Brown, B. N, et al. Macrophage polarization: an opportunity for improved outcomes in bio‐
materials and regenerative medicine. Biomaterials, (2012). , 3792-3802.
[91] Sica, A, & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J Clin
Invest, (2012). , 787-795.
Regenerative Medicine and Tissue Engineering614
